[1]
Eichhorst, B.; Goede, V.; Hallek, M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk. Lymphoma, 2009, 50, 171-178.
[2]
Hillmen, P.; Robak, T.; Janssens, A.; Babu, K.G.; Kloczko, J.; Grosicki, S.; Doubek, M.; Panagiotidis, P.; Kimby, E.; Schuh, A.; Pettitt, A.R.; Boyd, T.; Montillo, M.; Gupta, I.; Wright, O.; Dixon, L.; Carey, J.L.; Chang, C.; Lisby, S.; McKeown, A.; Offner, F. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial. Lancet, 2015, 385, 1873-1883.
[3]
Stilgenbauer, S. Prognostic markers and standard management of chronic lymphocytic leukemia. Ash Educ. Program Book, 2015, 2015(1), 368-377.
[4]
Rigg, R.A.; Aslan, J.E.; Healy, L.D.; Wallisch, M.; Thierheimer, M.L.; Loren, C.P.; Pang, J.; Hinds, M.T.; Gruber, A.; McCarty, O.J. Oral administration of Bruton’s tyrosine kinase inhibitors impairs GPVI-mediated platelet function. Am. J. Physiol. Cell Physiol., 2016, 310(5), C373-C380.
[5]
Hebb, J.; Assouline, S.; Rousseau, C.; DesJardins, P.; Caplan, S.; Egorin, M.J.; Amrein, L.; Aloyz, R.; Panasci, L. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother. Pharmacol., 2011, 68(3), 643-651.
[6]
Hallek, M.; Shanafelt, T.D.; Eichhorst, B. Chronic lymphocytic leukaemia. The Lancet, 2018, 39(10129), 1524-1537.
[7]
Strati, P.; Jain, N.; O’Brien, S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin. Proc., 2018, 93(5), 651-664.
[8]
Sturm, I.; Bosanquet, A.G.; Hermann, S.; Güner, D.; Dörken, B.; Daniel, P.T. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ., 2003, 10, 477.
[9]
Bush, J.A.; Li, G. Cancer chemoresistance: The relationship between p53 and multidrug transporters. Int. J. Cancer, 2002, 98(3), 323-330.
[10]
Wattel, E.; Preudhomme, C.; Hecquet, B.; Vanrumbeke, M.; Quesnel, B.; Dervite, I.; Morel, P.; Fenaux, P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 1994, 84(9), 3148-3157.
[11]
Herman, G.; Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 2003, 349, 2042-2054.
[12]
Carter, B.Z.; Milella, M.; Altieri, D.C.; Andreeff, M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood, 2001, 97, 2784-2790.
[13]
Ma, X.; Ezzeldin, H.H.; Diasio, R.B. Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs, 2009, 69, 1911-1934.
[14]
Shaffer, A.L.; Yu, X.; He, Y.; Boldrick, J.; Chan, E.P.; Staudt, L.M. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity, 2000, 13, 199-212.
[15]
Phan, R.T.; Saito, M.; Basso, K.; Niu, H.; Dalla-Favera, R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal centre B cells. Nat. Immunol., 2005, 6(10), 1054-1060.
[16]
Fujiki, R.; Kim, M.; Sasaki, Y.; Yoshimura, K.; Hirochika, K.; Kato, S. Ligand-induced transrepression by VDR through association of WSTF with acetylated histones. EMBO J., 2005, 24, 3881-3894.
[17]
Nahi, H.; Selivanova, G.; Lehmann, S.; Mollgard, L.; Bengtzen, S.; Concha, H.; Svensson, A.; Wiman, K.G.; Merup, M.; Paul, C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br. J. Haematol., 2008, 141, 445-453.
[18]
Kachalaki, S.; Baradaran, B.; Majidi, J.; Yousefi, M.; Shanehbandi, D.; Mohammadinejad, S.; Mansoori, B. Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60). Biomed. Pharmacother., 2015, 75, 100-104.
[19]
Pepper, C.; Thomas, A.; Tucker, H. Flow cytometric assessment of three different methods for the measurement of in-vitro apoptosis. Leuk. Res., 1998, 22, 439-444.
[21]
Aubry, J-P.; Blaecke, A.; Lecoanet-Henchoz, S.; Jeannin, P.; Herbault, N.; Caron, G.; Moine, V.; Bonnefoy, J.Y. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry, 1999, 37, 197-204.
[22]
Jones, L.B.; Secomb, T.W.; Dewhirst, M.W.; El-Kareh, A.W. The additive damage model: A mathematical model for cellular responses to drug combinations. J. Theor. Biol., 2014, 357, 10-20.
[23]
Abruzzo, L.V.; Lee, K.Y.; Fuller, A.; Silverman, A.; Keating, M.J.; Coombes, K.R. Validation of oligonucleotide microarray data using microfluidic low-density arrays: A new statistical method to normalize real-time RT-PCR data. Biotechniques, 2005, 38, 785-792.
[24]
Kwa, F.A.; Cole-Sinclair, M.; Kapuscinski, M. Chlorambucil-sensitive and -resistant lymphoid cells display different responses to the histone deacetylase inhibitor, sodium butyrate. Biochem. Biophys. Res. Commun., 2010, 403, 288-292.
[25]
Mullick, A.; Elias, M.; Harakidas, P.; Marcil, A.; Whiteway, M.; Ge, B.; Hudson, T.J.; Caron, A.W.; Bourget, L.; Picard, S.; Jovcevski, O.; Massie, B.; Thomas, D.Y. Gene Expression in HL60 Granulocytoids and Human Polymorphonuclear Leukocytes Exposed to Candida albicans. Infect. Immun., 2004, 72(1), 414-429.
[26]
Rigg, R.A.; Aslan, J.E.; Healy, L.D.; Wallisch, M.; Thierheimer, M.L.D.; Loren, C.P.; Pang, J.; Hinds, M.T.; Gruber, A.; McCarty, O.J.T. Oral administration of Brutons tyrosine kinase inhibitors impairs GPVI-mediated platelet function. Am. J. Physiol. Cell Physiol., 2016, 310(5), C373.
[27]
Ahmadzadeh, A.; Khodadi, E.; Shahjahani, M.; Bertacchini, J.; Vosoughi, T.; Saki, N. The Role of HDACs as Leukemia Therapy Targets using HDI. Int. J. Hematol. Oncol. Stem Cell Res., 2015, 9(4), 203-214.
[28]
Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 2007, 12(10), 1247-1252.
[29]
Kwa, F.A.; Balcrczyk, A.; Licciardi, P.; El-Osta, A.; Karagiannis, T.C. Chromatin modifying agents - the cutting edge of anticancer therapy. Drug Discov. Today, 2011, 16, 543-547.
[30]
Medina, V.; Edmonds, B.; Young, G.P.; James, R.; Appleton, S.; Zalewski, P.D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin a (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res., 1997, 57, 3697-3707.
[31]
Wei, Z.; Gao, W.; Wu, Y.; Ni, B.; Tian, Y. Mutual interaction between BCL6 and miRNAs contributing to the pathogenesis of various cancers. Clin. Transl. Oncol., 2015, 17(11), 841-846.
[32]
Cerchietti, L.C.; Yang, S.N.; Shaknovich, R.; Hatzi, K.; Polo, J.M.; Chadburn, A.; Dowdy, S.F.; Melnick, A. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood, 2009, 113(15), 3397-3405.
[33]
Choi, J.H.; Min, N.Y.; Park, J.; Kim, J.H.; Park, S.H.; Ko, Y.J.; Kang, Y.; Moon, Y.J.; Rhee, S.; Ham, S.W.; Park, A.J.; Lee, K.H. TSA-induced DNMT1 down-regulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116. Biochem. Biophys. Res. Commun., 2010, 39(1), 449-454.
[34]
Parker, B.S.; Cutts, S.M.; Nudelman, A.; Rephaeli, A.; Phillips, D.R.; Sukumar, S. Mitoxantrone mediates demethylation and reexpression of Cyclin D2, estrogen receptor and 14.3.3 sigma in breast cancer cells. Cancer Biol. Ther., 2003, 2(3), 259-263.
[35]
Kato, S.; Fujiki, R.; Kim, M.S.; Kitagawa, H. Ligand-induced transrepressive function of VDR requires a chromatin remodelling complex, WINAC. J. Steroid Biochem. Mol. Biol., 2007, 103, 372-380.
[36]
Daniel, C.; Schroder, O.; Zahn, N.; Gaschott, T.; Steinhilber, D.; Stein, J.M. The TGF beta/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression. J. Cell. Biochem., 2007, 102(6), 1420-1431.
[37]
Ting, H.J.; Bao, B.Y.; Reeder, J.E.; Messing, E.M.; Lee, Y.F. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1 alpha,25-dihydroxyvitamin D-3 responsiveness. Mol. Cancer Res., 2007, 5(9), 967-980.
[38]
Secchiero, P.; di Iasio, M.G.; Gonelli, A.; Barbarotto, E.; Melloni, E.; Tiribelli, M.; Chiaruttini, C.; Zauli, G. Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of zap-70. J. Cell. Physiol., 2007, 21(1), 229-236.
[39]
Park, D.G. The changes of expression of survivin by butyrate in HCT116 colon cancer cells. J. Korean Surg. Soc., 2009, 77(5), 297-305.
[40]
Sah, N.K.; Munshi, A.; Hobbs, M.; Carter, B.Z.; Andreeff, M.; Meyn, R.E. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys., 2006, 66(3), 852-859.
[41]
Saldanha, S.; Kala, R.; Tollefsbol, T. Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp. Cell Res., 2014, 324(1), 40-53.
[42]
Ge, Z.; Wang, H.; Parthum, M.R.; Hoffman, C.S.; Annunziato, A.T. Nuclear Hat1p complex (NuB4) components participate in DNA repair-linked chromatin reassembly. J. Biol. Chem., 2011, 286, 16790-16799.
[43]
Lemercier, C.; Brocard, M.; Puvion-Dutilleul, F.; Kao, H.; Albagli, O.; Khochbin, S. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J. Biol. Chem., 2002, 277, 22045-22052.
[44]
Zhang, H.; Okada, S.; Hatano, M.; Okabe, S.; Tokuhisa, T. A new functional domain of BCL6 family that recruits histone deacetylases. Biochim. Biophys. Acta, 2001, 540, 188-200.
[45]
Mottet, D.; Castronovo, V. Histone deacetylases: Target enzymes for cancer therapy. Clin. Exp. Metastasis, 2008, 25, 183-189.
[46]
Saito, M.; Novak, U.; Piovan, E.; Basso, K.; Sumazin, P.; Schneider, C.; Crespo, M.; Shen, Q.; Bhagat, G.; Califano, A. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA, 2009, 106(27), 11294-11299.
[47]
Heider, U.; Rademacher, J.; Lamottke, B.; Mieth, M.; Moebs, M.; von Metzler, I.; Assaf, C.; Sezer, O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteosome inhibitor bortezomib in cutaneous T cell lymphoma. Eur. J. Haematol., 2009, 82, 440-449.
[48]
Zhou, J.X.; Lee, C.H.; Qi, C.F.; Wang, H.; Naghashfar, Z.; Abbasi, S.; Morse, III, H.C. IFN Regulatory Factor 8 regulates MDM2 in germinal center B cells. J. Immunol., 2009, 183, 3188-3194.
39
4